List of Excipients in Branded Drug CLINDAGEL

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	CLINDAGEL	clindamycin	16781-462	CARBOMER HOMOPOLYMER TYPE A
Bausch Health US LLC	CLINDAGEL	clindamycin	16781-462	METHYLPARABEN
Bausch Health US LLC	CLINDAGEL	clindamycin	16781-462	POLYETHYLENE GLYCOL 400
Bausch Health US LLC	CLINDAGEL	clindamycin	16781-462	PROPYLENE GLYCOL
Bausch Health US LLC	CLINDAGEL	clindamycin	16781-462	SODIUM HYDROXIDE
Bausch Health US LLC	CLINDAGEL	clindamycin	16781-462	WATER

Clindagel Excipient Strategy and Commercial Opportunities

Last updated: October 14, 2026

Clindagel is a topical 1% clindamycin phosphate gel for acne vulgaris. Its commercial opportunity is no longer based on molecule exclusivity. The product is an established genericized topical antibiotic, so value depends on formulation performance, tolerability, packaging, combination therapy, adherence, and differentiated regulatory positioning. The most attractive excipient opportunities are low-irritation, alcohol-free gel systems; improved delivery and drying behavior; preservative and microbial-control strategies; and fixed or co-packaged combinations that reduce antibiotic monotherapy.

What is Clindagel and how is it formulated?

Clindagel contains clindamycin phosphate equivalent to 1% clindamycin in a topical gel. The FDA-approved indication is acne vulgaris in patients at least 12 years old.[1]

The product is an aqueous, alcohol-free gel. The labeled inactive ingredients include carbomer 934P, propylene glycol, polysorbate 20, purified water, and sodium hydroxide.[1] Carbomer provides gel structure, sodium hydroxide adjusts pH and neutralizes the polymer, propylene glycol functions as a humectant and solvent, and polysorbate 20 supports wetting and ingredient distribution.

Product attribute	Clindagel profile
Active ingredient	Clindamycin phosphate
Strength	Equivalent to 1% clindamycin
Dosage form	Topical gel
Indication	Acne vulgaris
Route	Cutaneous
Key polymer	Carbomer 934P
Key solvent/humectant	Propylene glycol
Surfactant	Polysorbate 20
pH adjustment	Sodium hydroxide
Alcohol status	Alcohol-free formulation
Primary commercial issue	Generic competition and antibiotic-stewardship pressure

The formulation is technically conventional, which lowers manufacturing complexity but also limits differentiation. A competing product can often use a comparable carbomer system while changing rheology, solvent content, packaging, drying time, or skin feel.

What excipient functions are most important in Clindagel?

The highest-value excipient functions are rheology control, skin tolerability, drug uniformity, drying performance, and microbiological stability.

Carbomer selection and rheology

Carbomer 934P produces a clear or translucent gel at low concentration and is compatible with many topical drug systems. Its limitations include sensitivity to neutralization conditions, possible stringiness, and variation in yield value across suppliers and grades.

A differentiated formulation could evaluate:

• Carbomer 934P, 974P, 980, or equivalent pharmaceutical grades.
• Crosslinked acrylic acid polymers with lower tack.
• Acrylates or acrylamide-based rheology modifiers.
• Cellulose derivatives where improved spreadability is required.
• Polymer blends that reduce stringing during application.

The target should not be maximum viscosity. Acne patients generally need a thin film that spreads quickly, dries within a predictable interval, and does not leave visible residue.

Humectants and solvents

Propylene glycol supports solubilization and hydration but may contribute to stinging or irritation in sensitive skin. Alternative systems could use combinations of glycerin, polyethylene glycol, pentylene glycol, propanediol, or low levels of other skin-compatible solvents.

The formulation objective is a controlled balance:

Formulation target	Excipient strategy
Lower sting	Reduce propylene glycol load or replace part of it with a lower-irritancy solvent
Faster drying	Reduce total humectant content and optimize volatile or semi-volatile components
Better moisturization	Use glycerin or compatible polyols at controlled levels
Lower tack	Combine humectants with lower-stringing polymers and optimized neutralization
Better solubilization	Screen solvent and surfactant ratios against clindamycin phosphate stability
Reduced residue	Optimize solids content and polymer concentration

A lower-irritation solvent system may provide a commercial advantage, but any material change requires comparative stability, preservative-effectiveness, microbial-limit, and dermatological tolerability testing.

Surfactants and wetting agents

Polysorbate 20 improves wetting and ingredient distribution. Its concentration should remain as low as practical because surfactants can contribute to irritation, odor, or formulation variability.

Potential alternatives include poloxamers and other nonionic surfactants. The primary screening criteria are:

1. Physical stability.
2. Compatibility with the polymer and neutralization system.
3. No precipitation or haze across the product shelf life.
4. Low irritation potential.
5. Reproducible drug assay and content uniformity.

A surfactant change alone is unlikely to support strong market differentiation. It becomes more valuable when combined with a demonstrated improvement in skin feel, spreadability, or stability.

What formulation opportunities exist for Clindagel?

Low-irritation and sensitive-skin gel

A reformulated Clindagel-type product could target patients who discontinue topical antibiotics because of burning, dryness, tightness, or peeling. The opportunity is to reduce solvent-related irritation while retaining a fast-drying, non-greasy profile.

Potential design parameters include:

• Lower propylene glycol exposure.
• A lower-tack carbomer or polymer blend.
• Controlled humectancy.
• Skin-compatible pH.
• Minimal surfactant content.
• Airless or metered-dose packaging.

The regulatory value depends on whether the reformulation demonstrates clinically meaningful tolerability or adherence benefits rather than only laboratory differences.

Preservative-minimized or preservative-free packaging

Topical aqueous gels require microbiological control. A preservative-free product would need a validated alternative, such as:

• A sterile or microbiologically controlled manufacturing process.
• Single-dose or unit-dose packaging.
• An airless pump with validated microbial ingress resistance.
• A formulation with intrinsic antimicrobial protection.
• A packaging system that limits repeated exposure.

For a multidose acne gel, packaging is likely to be more commercially practical than single-use presentation. A preservative-reduced product could appeal to sensitive-skin users, but the claim must be supported by preservative-effectiveness testing and in-use stability.

Improved drying and cosmetic acceptability

Patients often apply acne products before school, work, exercise, or cosmetics. A gel that dries rapidly without pilling or visible residue can compete effectively against generic gels.

Excipient and process variables include:

• Polymer molecular weight and neutralization degree.
• Solvent-to-water ratio.
• Humectant concentration.
• Particle-free or low-haze composition.
• Applicator geometry.
• Packaging dose per actuation.

A commercial program should measure drying time, tack, pilling after sunscreen or makeup application, transfer to textiles, and skin gloss. These endpoints can be more relevant to adherence than nominal viscosity.

How does Clindagel compare with competing topical acne products?

Clindagel competes with clindamycin solutions, lotions, foams, pledgets, combination products, and non-antibiotic therapies.

Product class	Main advantage	Main weakness	Excipient opportunity
Clindamycin gel	Familiar, alcohol-free, direct topical delivery	Antibiotic resistance and generic substitution	Lower-irritation, faster-drying gel
Clindamycin solution	Simple application and rapid drying	Potential sting and solvent-related dryness	Replace or reduce irritating solvents
Clindamycin foam	Cosmetic spreadability and rapid application	More complex packaging and manufacturing	Foam stability, propellant strategy, dose control
Clindamycin/benzoyl peroxide	Addresses bacterial burden and resistance concerns	Greater irritation and oxidation challenges	Stabilizers, barrier-supportive excipients, low-irritation vehicle
Adapalene/benzoyl peroxide	Retinoid-based combination therapy	Dryness and irritation	Emulsion or gel systems with improved tolerability
Azelaic acid products	Non-antibiotic positioning	Different onset and sensory profile	Improved suspension, reduced grittiness, cosmetic elegance

Antibiotic stewardship constrains long-term growth for clindamycin monotherapy. The American Academy of Dermatology recommends limiting antibiotic exposure and using benzoyl peroxide with topical or oral antibiotics to reduce resistance risk.[2] That shifts the strongest commercial opportunity toward combination products and adherence-enhancing vehicles rather than a standalone clindamycin gel.

What FDA regulatory pathways apply to a Clindagel reformulation?

A new product can use an abbreviated new drug application if it demonstrates pharmaceutical equivalence and bioequivalence to the reference product. A materially different formulation, dosage form, delivery system, or clinical claim may require a 505(b)(2) application.

Development scenario	Likely pathway
Same strength, dosage form, route, and equivalent inactive-ingredient profile	ANDA
Different excipient system with equivalent performance	ANDA may be possible, subject to FDA requirements
New delivery device or materially different formulation	505(b)(2) may be appropriate
New combination with benzoyl peroxide or another active	ANDA or 505(b)(2), depending on reference and claims
New indication or clinically differentiated use	505(b)(2) or supplemental pathway
Cosmetic or OTC positioning	Separate monograph and regulatory analysis required

Topical products may require comparative clinical endpoint studies, pharmacokinetic studies, in vitro release testing, or other product-specific evidence. FDA’s guidance on topical dermatological products emphasizes formulation, characterization, product performance, and comparative evidence.[3]

Excipient selection must also account for FDA’s Inactive Ingredient Database. The database can support precedent analysis for route, dosage form, and maximum potency, but it does not automatically establish approval for a new concentration or new product design.[4]

What patents protect Clindagel and when does exclusivity end?

Clindamycin phosphate is an established active ingredient, and the commercial market is primarily exposed to generic competition rather than a strong composition-of-matter patent position.

The key protection categories are:

• Formulation patents covering gel composition or excipient ratios.
• Delivery-system patents covering pumps, foams, or applicators.
• Method-of-use patents covering acne treatment regimens.
• Combination-product patents covering clindamycin with benzoyl peroxide, adapalene, or other actives.
• Manufacturing patents covering mixing, neutralization, deaeration, filling, or packaging.

The Orange Book should be reviewed for any current listed patents and exclusivity associated with the relevant NDA and marketed product.[5] A product-level patent conclusion requires matching the exact NDA holder, current label, listed patents, and litigation status. The active ingredient’s age means generic entry risk is high unless a formulation or device claim creates a defensible barrier.

For a new entrant, patent strategy should focus on narrow but commercially meaningful claims:

1. Specific polymer and solvent ranges.
2. Reduced-irritation excipient combinations.
3. pH and viscosity windows linked to stability or delivery.
4. Airless packaging that limits contamination.
5. Combination regimens that reduce antibiotic exposure.
6. Demonstrated in vitro release or clinical performance advantages.

Broad claims covering “a clindamycin gel” are vulnerable because the field contains extensive prior art.

Which companies are challenging Clindagel, and what is the generic-entry risk?

Generic competition is the principal risk. Clindamycin phosphate topical products have been marketed in multiple dosage forms and by multiple generic manufacturers. The most exposed product categories are conventional gels, solutions, lotions, and combination products with established reference standards.

Paragraph IV risk is more relevant to any newly listed formulation patent than to legacy clindamycin phosphate products. A generic applicant may challenge patents by asserting invalidity, noninfringement, or unenforceability. For an established topical product, market entry can also occur through ordinary ANDA approval where no blocking patent remains.

Commercially, a generic launch could produce:

• Rapid price erosion.
• Pharmacy substitution.
• Loss of formulary preference.
• Lower prescriber loyalty.
• Greater pressure on packaging and patient-support differentiation.

A branded reformulation needs a measurable reason for payers and prescribers to resist substitution. “Alcohol-free” alone is unlikely to provide durable protection if equivalent generic products already make that claim.

What licensing and partnership opportunities exist?

The most realistic licensing opportunities are platform-based rather than molecule-based.

Excipient and vehicle licensing

A specialty excipient company could license:

• Low-tack polymer systems.
• Preservative-free multidose packaging.
• Skin-barrier-supportive vehicles.
• Bioadhesive systems with controlled residence time.
• In vitro release and scale-up know-how.

Combination-product partnerships

A dermatology company could combine clindamycin with benzoyl peroxide, adapalene, or another acne active. The strongest commercial logic is a regimen that improves adherence while limiting antibiotic resistance.

Contract development and manufacturing

CDMOs with topical semisolid expertise can offer:

• QbD formulation development.
• Scale-up of carbomer gels.
• Vacuum mixing and deaeration.
• Tube, pump, and airless filling.
• In vitro release testing.
• Microbiological validation.
• Comparative clinical endpoint support.

The preferred partner would have both topical manufacturing capacity and regulatory experience with generic dermatological products.

How strong is the commercial opportunity for a new Clindagel-type product?

The opportunity is moderate for a differentiated product and weak for a conventional me-too gel.

Opportunity	Commercial attractiveness	Main barrier
Standard clindamycin gel	Low	Generic price competition
Lower-irritation gel	Moderate	Need clinical or robust user evidence
Fast-drying cosmetic gel	Moderate	Limited patent breadth
Preservative-reduced multidose product	Moderate to high	Microbial-control validation
Clindamycin/benzoyl peroxide combination	Moderate to high	Resistance, stability, and irritation
Airless pump presentation	Moderate	Device cost and patent design-around
Premium specialty dermatology product	Moderate	Payer and substitution pressure

Revenue exposure depends on the specific manufacturer, channel mix, reimbursement, market share, and whether the product is branded or generic. Public product-level revenue is generally not available for all Clindagel-related presentations, so the most reliable commercial assessment is scenario-based rather than based on a single reported figure.

Key Takeaways

• Clindagel is a 1% clindamycin phosphate topical gel for acne vulgaris.
• Its core excipient system is a conventional carbomer, propylene glycol, polysorbate 20, water, and sodium hydroxide gel.
• The strongest formulation opportunities are lower irritation, reduced tack, faster drying, improved cosmetic elegance, and validated microbial-control packaging.
• Antibiotic stewardship weakens the long-term case for clindamycin monotherapy and favors combination products.
• Generic competition makes a standard reformulation commercially weak unless it produces a measurable adherence or tolerability benefit.
• Patent value is more likely to arise from a specific formulation, delivery system, packaging configuration, or combination than from clindamycin phosphate itself.
• An ANDA may support a pharmaceutically equivalent product, while a materially differentiated formulation or combination may require a 505(b)(2) pathway.
• The most attractive licensing targets are excipient platforms, airless packaging, topical CDMO capabilities, and acne combination technologies.

FAQs About Clindagel Excipient Strategy

Can propylene glycol be removed from Clindagel?

Yes, but removal would require reformulation work to preserve clindamycin phosphate solubility, gel structure, stability, microbial quality, and skin performance. A replacement system could use glycerin, propanediol, polyethylene glycol, or a solvent blend.

Is carbomer 934P essential to Clindagel?

No. Carbomer 934P is the labeled gelling polymer, but alternative carbomer grades, acrylic polymers, cellulose derivatives, or polymer blends may be evaluated if they deliver equivalent stability and topical performance.

Can a preservative-free clindamycin gel be developed?

Yes, but a multidose product would need a validated microbial-control strategy. Airless packaging, restricted microbial ingress, unit-dose packaging, or intrinsic antimicrobial protection may support development.

Would a clindamycin and benzoyl peroxide product have stronger commercial protection?

It may have stronger differentiation than clindamycin monotherapy, particularly because benzoyl peroxide supports antibiotic-stewardship objectives. Protection would depend on formulation claims, stability, prior art, regulatory pathway, and any applicable patents.

Is Clindagel still protected by market exclusivity?

The commercial risk profile is consistent with an established product facing generic competition. Current Orange Book listings, patents, and exclusivity should be checked against the specific NDA and marketed presentation before making a launch or litigation decision.

References

1. U.S. Food and Drug Administration. (n.d.). Clindagel (clindamycin phosphate) gel, 1% prescribing information. DailyMed.

2. American Academy of Dermatology Association. (2016). Guidelines of care for the management of acne vulgaris. Journal of the American Academy of Dermatology, 74(5), 945-973.

3. U.S. Food and Drug Administration. (2022). Acyclovir topical cream and ointment products: Product-specific guidance; topical dermatological drug products guidance and related product performance recommendations. FDA.

4. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.

5. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, commonly known as the Orange Book. FDA.